Effect of platelet inhibitors on thrombus burden in patients with acute pulmonary embolism
| Autor: | Joseph Van Galen, Annelise Hamer, Ayman Elbadawi, Scott J. Cameron, Colin Wright, Libia Pava, Abhishek Chaturvedi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty 030204 cardiovascular system & hematology Article 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine.artery medicine Humans Platelet In patient cardiovascular diseases Thrombus Retrospective Studies Aspirin business.industry Hematology General Medicine Venous Thromboembolism medicine.disease Pulmonary embolism 030104 developmental biology medicine.anatomical_structure Thrombus burden Ventricle Pulmonary artery Acute Disease Cardiology business Pulmonary Embolism Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Platelets |
| ISSN: | 1369-1635 |
| Popis: | Venous thromboembolism (VTE) whether provoked or not can be life-threatening due to an acute increase in load on the right ventricle (RV) from obstruction of the pulmonary artery (PA). Treatment for and prevention of VTE involves anti-thrombotic agents; more specifically, medications targeting the anticoagulation cascade. In spite of the widespread acceptance of anticoagulants in the treatment of VTE, there appears to be an ongoing belief that platelet reactivity contributes to thrombus burden in patients with acute pulmonary embolism (PE). This investigation of 398 patients presenting with acute PE evaluated whether anti-platelet medication use, which consisted mostly of aspirin therapy, at the time of presentation, affects PA thrombus burden, RV load, or short-term patient outcomes. We conclude that platelets may have been erroneously incriminated as direct thrombotic mediators in patients with acute PE since aspirin neither decreased PA thrombus burden, nor did aspirin improve short-term mortality following acute PE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|